SELLAS Life Sciences (SLS) Change in Accured Expenses (2010 - 2026)

SELLAS Life Sciences (SLS) has 17 years of Change in Accured Expenses data on file, last reported at -$1.3 million in Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at -$1.3 million, up 56.34% year-over-year; the trailing twelve-month figure through Mar 2026 was -$310000.0 (up 92.32% YoY), and the FY2025 annual result was -$1.9 million, up 11.13% from the prior year.
• Change in Accured Expenses fell to -$1.3 million in Q1 2026 per SLS's latest filing, from $545000.0 in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $1.7 million in Q4 2022 and troughed at -$2.9 million in Q1 2025.
• A 5-year average of -$17294.1 and a median of $196000.0 in 2023 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2022 and 2024: Change in Accured Expenses jumped 2713.11% in 2022, then tumbled 631.63% in 2024.
• A 5-year view of Change in Accured Expenses shows it stood at $1.7 million in 2022, then sank by 53.03% to $806000.0 in 2023, then tumbled by 102.98% to -$24000.0 in 2024, then surged by 2370.83% to $545000.0 in 2025, then tumbled by 331.93% to -$1.3 million in 2026.
• Business Quant data shows SLS's Change in Accured Expenses at -$1.3 million in Q1 2026, $545000.0 in Q4 2025, and $897000.0 in Q3 2025.